Bleakley Financial Group LLC Has $722,000 Stake in Organon & Co. (NYSE:OGN)

Bleakley Financial Group LLC grew its holdings in Organon & Co. (NYSE:OGN) by 302.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 48,372 shares of the company’s stock after purchasing an additional 36,367 shares during the quarter. Bleakley Financial Group LLC’s holdings in Organon & Co. were worth $722,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Pacer Advisors Inc. boosted its position in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after acquiring an additional 11,140,388 shares during the period. Weiss Asset Management LP acquired a new position in shares of Organon & Co. during the third quarter valued at about $32,966,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of Organon & Co. by 303.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock valued at $23,762,000 after buying an additional 934,505 shares during the period. Charles Schwab Investment Management Inc. grew its position in Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock worth $63,570,000 after buying an additional 875,128 shares in the last quarter. Finally, Philip James Wealth Mangement LLC bought a new position in Organon & Co. during the third quarter valued at about $15,386,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Trading Down 1.7 %

Shares of OGN opened at $14.63 on Monday. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The stock has a 50 day simple moving average of $15.37 and a 200-day simple moving average of $17.66. The stock has a market cap of $3.77 billion, a PE ratio of 2.90, a PEG ratio of 0.83 and a beta of 0.76.

Analyst Ratings Changes

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.